EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clonal hematopoiesis and atherosclerosis

Ohad Oren, Aeron M Small, Peter Libby

Journal of Clinical Investigation · 01.10.2024 · 134 (19)

DOI: 10.1172/jci180066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.10.2024. Verfasst von Ohad Oren und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Clonal Hematopoiesis, DNA Methyltransferase 3A, Dioxygenases. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a previously unrecognized, potent, age-related, and common risk factor for atherosclerosis. Somatic mutations in certain known leukemia driver genes give rise to clones of mutant cells in peripheral blood. The increased risk of developing hematologic malignancy does not, on its own, explain excess mortality in individuals with CHIP. Cardiovascular disease accounts for much of this gap. Experimental evidence supports the causality of certain CHIP mutations in accelerated atherosclerosis. CHIP due to mutations in different driver genes varies in their promotion of atherosclerotic events and in the region of augmented atherosclerotic involvement. For example, CHIP due to mutations in DNMT3a appears less atherogenic than CHIP that arises from TET2 or JAK2 , forms of CHIP that incite inflammation. The recognition of certain CHIP mutations as promoters of atherosclerotic risk has opened new insights into understanding of the pathophysiology of this disease. The accentuated cardiovascular risk and involvement of distinct pathways of various forms of CHIP also inform novel approaches to allocation of targeted therapies, affording a step toward personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisClonal HematopoiesisDNA Methyltransferase 3ADioxygenasesMutationHumansDNA (Cytosine-5-)-MethyltransferasesAnimalsJanus Kinase 2DNA-Binding ProteinsProto-Oncogene ProteinsRisk Factors

Substanzen

DNA Methyltransferase 3ADNMT3A protein, humanTET2 protein, humanDioxygenasesJAK2 protein, humanDNA (Cytosine-5-)-MethyltransferasesJanus Kinase 2DNA-Binding ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Oren, O., Small, A. M., & Libby, P. (2024). Clonal hematopoiesis and atherosclerosis. Journal of Clinical Investigation, 134(19). https://doi.org/10.1172/jci180066

Vancouver

Oren O, Small AM, Libby P. Clonal hematopoiesis and atherosclerosis. Journal of Clinical Investigation. 2024;134(19). doi:10.1172/jci180066

BibTeX
@article{Oren2024,
  author = {Oren, Ohad and Small, Aeron M and Libby, Peter},
  title = {Clonal hematopoiesis and atherosclerosis},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {19},
  doi = {10.1172/jci180066}
}
Kostenlos starten →